Detalhe da pesquisa
1.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet
; 399(10319): 36-49, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34883053
2.
A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
Mov Disord
; 38(8): 1493-1502, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246815
3.
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lancet
; 398(10318): 2277-2287, 2021 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774197
4.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
5.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet
; 398(10318): 2258-2276, 2021 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863358
6.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet
; 398(10303): 856-869, 2021 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370971
7.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
8.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
9.
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
Lancet
; 403(10432): 1133-1136, 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38484752
10.
Three-dose vaccination elicits neutralising antibodies against omicron.
Lancet
; 399(10326): 715-717, 2022 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065005
11.
TSPO mutations in rats and a human polymorphism impair the rate of steroid synthesis.
Biochem J
; 474(23): 3985-3999, 2017 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074640
12.
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC.
Lancet
; 398(10296): 207-209, 2021 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34197809
13.
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
Lancet
; 397(10292): 2331-2333, 2021 06 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090624
14.
Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
Lancet
; 384(9942): 504-13, 2014 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24794816
15.
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
PLoS One
; 19(3): e0294897, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38512960
16.
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Lancet Microbe
; 4(11): e863-e874, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37783221
17.
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2.
EClinicalMedicine
; 56: 101823, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36684396
18.
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
J Infect
; 86(6): 574-583, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37028454
19.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect
; 87(1): 18-26, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37085049
20.
Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme.
Lancet Neurol
; 21(4): 342-354, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35305340